April 2016 | HCC Monitor

Novel Therapies on the Horizon in Hepatocellular Carcinoma

April 19, 2016

Clinical Articles

Both in the United States and worldwide, the incidence of hepatocellular carcinoma (HCC) is on the rise, and, despite extensive research, sorafenib (Nexavar) remains the only FDA-approved systemic therapy available for advanced tumors.

New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis

April 19, 2016

Clinical Articles

The hepatic portal vein is critical to normal liver function and supplies approximately 75% of the blood supply to the liver. In the general population, portal vein thrombosis (PVT) is relatively rare, occurring with an incidence of about in 1 in 100,000 people.

Moving Forward: Examining the Evolving Role of Embolization in HCC

April 19, 2016

Clinical Articles

Despite the widespread prevalence of hepatocellular carcinoma (HCC), effective treatment options for both primary and secondary liver tumors have remained elusive, as these tumors are difficult to manage, especially in cases where the tumor is unresectable.

Committee Recommends Continuation of Phase III Tivantinib Study

April 19, 2016

Clinical Articles

During a preplanned interim analysis, an independent data monitoring committee recommended the continuation of the phase III METIV-HCC trial, which is assessing the safety and efficacy of tivantinib in patients with hepatocellular carcinoma (HCC) with high MET expression.

Genetically Modified T-Cell Therapy Cleared for Early Stage HCC Study

April 19, 2016

Clinical Articles

The FDA has accepted an investigational new drug application for autologous genetically modified T-cells expressing affinity enhanced T-cell receptors (TCRs) specific to alpha fetoprotein (AFP) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC).